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Non-viable lactic acid bacteria (LAB) have been proposed as antigen delivery
platforms called bacterium-like particles (BLPs). Most studies have been performed
with Lactococcus lactis-derived BLPs where multiple antigens were attached to the
peptidoglycan surface and used to successfully induce specific immune responses. It
is well-established that the immunomodulatory properties of LAB are strain dependent
and therefore, the BLPs derived from each individual strain could have different adjuvant
capacities. In this work, we obtained BLPs from immunomodulatory (immunobiotics)
and non-immunomodulatory Lactobacillus rhamnosus and Lactobacillus plantarum
strains and comparatively evaluated their ability to improve the intestinal and systemic
immune responses elicited by an attenuated rotavirus vaccine. Results demonstrated
that orally administered BLPs from non-immunomodulatory strains did not induce
significant changes in the immune response triggered by rotavirus vaccine in mice. On
the contrary, BLPs derived from immunobiotic lactobacilli were able to improve the levels
of anti-rotavirus intestinal IgA and serum IgG, the numbers of CD24+B220+ B and CD4+
T cells in Peyer’s patches and spleen as well as the production of IFN-γ by immune cells.
Interestingly, among immunobiotics-derived BLPs, those obtained from L. rhamnosus
CRL1505 and L. rhamnosus IBL027 enhancedmore efficiently the intestinal and systemic
humoral immune responses when compared to BLPs from other immunobiotic bacteria.
The findings of this work indicate that it is necessary to perform an appropriate selection
of BLPs in order to find those with the most efficient adjuvant properties. We propose the
term Immunobiotic-like particles (IBLPs) for the BLPs derived from CRL1505 and IBL027
strains that are an excellent alternative for the development of mucosal vaccines.
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INTRODUCTION
Lactic acid bacteria (LAB) have been studied for several years as
potential delivery systems and/or adjuvants for mucosal vaccine
development. In this regard, recombinant LAB expressing
pathogen’s antigens in their cell-walls have been used as
oral or nasal vaccines in animal models (1–4). The mucosal
administration of recombinant LAB was shown to elicit specific
systemic and mucosal immune responses against selected
antigens. However, the administration of genetically modified
organisms is associated with ethical concerns related to the
possible dissemination of virulence factors or antibiotic resistant
genes. Then, similar to other genetically modified organisms,
recombinant LAB expressing antigens from pathogens and
carrying antibiotic resistant genes cannot be applied in humans.
An original alternative to the use of genetically modified
LAB was the development of bacterium-like particles (BLPs)
derived from the acid and heat treatments of Lactococcus lactis
(5–8). These L. lactis-derived BLPs, also known as Gram-
positive enhancer matrix particles, do not contain DNA or
cytoplasmic proteins but conserve the adjuvant capacities of
the bacteria. The acid/heat treatment results in the bacterial
death, which implies greater safety related to the maximum
dose administered, and in addition to causing the loss of
genetic material, exposes the peptidoglycan of the cell-wall
increasing its capacity to bind proteins with lysine motifs
(LysM) at least 10 times (5). The ability of BLPs to improve
the protective immunity generated at the mucosal level by
recombinant proteins from different pathogens fused to LysM
has been widely evaluated. The microbial pathogens tested in
those investigations included bacteria, parasites and viruses such
as Streptococcus pneumoniae (5), Plasmodium berghei (7, 9),
and Influenza virus (10). Those studies clearly demonstrated
that L. lactis-derived BLPs are a promising adjuvant for
mucosal immunization.
The immunomodulatory properties of LAB proved to depend
on each individual strain. Previously, we evaluated the ability
of immunomodulatory viable LAB strains, administered by the
oral route in the same dose and during the same period, on
intestinal immunity (11–13). We found that although both
Lactobacillus rhamnosus CRL1505 and Lactobacillus plantarum
CRL1506 improved the intestinal immunity and the protection
against pathogens, the CRL1505 strain was more efficient
than the CRL1506 to achieve those beneficial effects (11–13).
Similarly, both L. lactis NZ9000 and L. rhamnosus CRL1505
administered by the nasal route were able to improve respiratory
immunity and confer protection against S. pneumoniae infection.
However, the protective effect induced by L. lactis NZ9000
was modest when compared to L. rhamnosus CRL1505 and it
was necessary a longer administration period of lactococci than
lactobacilli (14–16).
We hypothesized that BLPs obtained from different
immunomodulatory LAB would have different adjuvant capacity
when used in mucosal vaccine formulations. In this work, we
obtained BLPs from immunomodulatory (immunobiotics),
and non-immunomodulatory L. rhamnosus and L. plantarum
strains and comparatively evaluated their ability to improve





L. rhamnosusCRL1505, L. plantarumCRL1506 and L. plantarum
CRL1905 were obtained from the culture collection of CERELA
(Tucumán, Argentina). L. rhamnosus IBL027 was obtained from
the culture collection of the Infection Biology Laboratory of
INSIBIO (Tucumán, Argentina). Lactobacilli (1010 CFU stored
at −70◦C) were activated and cultured for 12 h at 37◦C (final
log phase) in Man-Rogosa-Sharpe (MRS) broth culture media.
The bacteria were harvested by centrifugation and washed with
sterile PBS (0.01 mol/L, pH 7.2). Chemical pre-treatment of
lactobacilli to generate BLP and immunomodulatory bacterium-
like particles (IBLP) was performed as follows. Bacteria from a
fresh overnight culture (100ml) were collected by centrifugation
(10min, 13,000 x g) and washed once with sterile distilled water.
Afterwards, the pellet was suspended in 20ml of 0.1M HCl and
boiled in a water bath for 45min. Next, the cells were washed
three times in 50ml sterile phosphate buffer saline (PBS), pH 7.4,
with vigorous vortexing. After the last washing step, cells were
resuspended in 10ml PBS and stored at −20◦C. The number
of IBLP particles per milliliter was adjusted according to the
CFU/ml determined in the starting culture. Viability of BLPs
and IBLPs was checked by plating the suspensions and several
dilutions on to MRS agar plates, which were incubated overnight
at 37◦C in microaerophilia.
Electron Microscopy
For transmission electron microscopy, samples were prepared
according to the Centro de Investigaciones y Servicios de
Microscopía Electronica (CISME–CONICET) standard
procedure. Briefly, L. rhamnosus CRL1505 and IBLP1505
were fixed by adding Karnovsky fixative. After 24 h of fixation
at 4◦C, samples were washed three times with 0.1M sodium
phosphate buffer (pH 7.4) and postfixed overnight in a solution
containing 1% osmium tetroxide in sodium phosphate buffer.
After dehydratation with a graded ethanol series, the samples
were embedded in Spurr resin. Ultrathin sections were cut
with an ultramicrotome and examined with a Zeiss Libra 120
transmission electron microscope.
Animals and Ethical Statement
Four-week-old female BALB/c mice were obtained from
the closed colony at CERELA (Tucumán, Argentina) in
SPF conditions. Animals were housed in plastic cages and
environmental conditions were kept constant, in agreement
with the standards for animal housing. Animal welfare was in
charge of researchers and special staff trained in animal care
and handling at CERELA. Animal health and behavior were
monitored twice a day.
This study was carried out in strict accordance with
the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Guidelines for Animal
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Experimentation of CERELA. The CERELA Institutional
Animal Care and Use Committee prospectively approved this
research under the protocol BIOT-CRL-18.
Immunization Protocols
Mice were vaccinated with the commercial, oral, pentavalent,
and live rotavirus vaccine RotaTeq R© (Merck & Co., Inc.). Two
sets of experiments with different immunization protocols were
used. In the first set of experiments, mice were vaccinated with
30 µl of rotavirus vaccine and 108 bacterial cells or particles
(high vaccine/low adjuvant immunization protocol). Mice that
received only 30 µl of rotavirus vaccine were used as controls.
In a second set of experiments, mice were vaccinated with
7.5 µl of rotavirus vaccine and 109 bacterial cells or particles
(low vaccine/high adjuvant immunization protocol). Mice that
received only 7.5 µl of rotavirus vaccine were used as controls.
In both protocols, mice were immunized orally on days 0, 14
and 28. Seven days after the last immunization (day 35), the
specific humoral and cellular immune responses were evaluated
as described below.
Serum and Intestinal Antibodies
Blood samples were obtained through cardiac puncture seven
days after the last immunization (day 35) and collected in
heparinized tubes. Intestinal fluid samples were obtained as
described previously (11). Briefly, the small intestine was flushed
with 5ml of PBS and the fluid was centrifuged (10,000×g 4◦C
for 10min) to separate particulate material. The supernatant
was kept frozen until use. Specific anti-rotavirus antibodies (IgA
and IgG) were determined by ELISA. Plates were coated with
1.5 µg of Rotateq per well overnight at 4◦C and blocked with
serum bovine albumin. Appropriate dilutions of the samples
(serum 1:20; intestinal fluid 1:2) were incubated for 1 h at 37◦C.
Peroxidase conjugated anti-mouse IgG, or IgA antibodies (1:500)
(Sigma-Aldrich) were added and incubated for 1 h at 37◦C. The
reaction was developed with TMB Substrate Reagent (Sigma-
Aldrich) and measured at 450 nm in a microplate reader.
Flow Cytometry
Ilium Payer’s patches and spleens were collected and
mechanically disaggregated. A single-cell suspension from
the Peyer’s patches or spleens of each mouse was obtained by
gently passing the collected tissue through a tissue strainer with
PBS supplemented with 2% FCS (FACS buffer). Cell suspensions
were subjected to red blood cells lysis (Tris-ammonium chloride,
BD PharMingen) and counted on a hemocytometer. Trypan
blue exclusion method was used to assess viability of cells. Cell
suspensions were pre-incubated with anti-mouse CD32/CD16
monoclonal antibody (Fc block) for 30min at 4◦C. Cells were
incubated with the antibody mixes for 30min at 4◦C and washed
with FACS buffer. The following antibodies from BD Biosciences
were used: PE-labeled anti-mouse CD24, biotinylated anti-
mouse B220, PE-labeled anti-mouse CD45, biotinylated
anti-mouse CD45, FITC-labeled anti-mouse CD3, PE-labeled
anti-mouse CD8, and biotinylated anti-mouse CD4 antibodies.
Streptavidin-PerCP was used as a second-step reagent. Flow
cytometry was performed using a BD FACSCaliburTM flow
cytometer (BD Biosciences) and data were analyzed using FlowJo
software (TreeStar).
Cytokine Production by Immune Cells
Ilium Payer’s patches and spleens were collected, and a single-
cell suspension from each mouse was obtained as described
above. After red blood cells lysis, isolated cells were suspended
in complete DMEM (Invitrogen) supplemented with 10%
FCS (Sigma), 50µg/ml penicillin-streptomycin, and 50µg/ml
gentamicin (Invitrogen). Cells (4 × 106 cells/well) were cultured
in 24-well plates in the presence of 0.5µl of the rotavirus vaccine.
Cytokines were quantified in culture supernatants by ELISA after
24 h at 37◦C. The concentrations of tumor necrosis factor (TNF)-
α, interferon (IFN)-γ, and interleukin (IL)-4 were measured on
the supernatants of the stimulated mononuclear cells isolated
from Peyer’s patches or spleen with commercially available
enzyme-linked immunosorbent assay (ELISA) kits following the
manufacturer’s recommendations (R&D Systems, MN, USA).
Statistical Analysis
Each experimental group consisted of 3 mice per group at each
time point and experiments were performed in triplicate (n =
9 for each parameter studied). Results were expressed as mean
± standard deviation (SD). The differences between groups
were analyzed using student t-test. Differences were considered
significant at p < 0.05. ANOVA one-way was used for analysis of
variance among multiple groups.
RESULTS
Development of IBLP From L. rhamnosus
CRL1505
The heat-acid treatment of the lactobacilli results in non-
living particles. This procedure most likely affected the
protein and DNA content of the IBLPs. The intracellular
contents of the IBLPs seemed to be partially released or
degraded (Figure 1). IBLPs have the same size and shape than
living lactobacilli. Peptidoglycan, the main component of the
lactobacilli’s cell wall, was exposed by the harsh acid treatment.
This peptidoglycan matrix preserved the structural integrity of
lactobacilli (Figure 1).
IBLP From L. rhamnosus CRL1505
Enhance the Humoral Immune Response
Against Rotavirus Vaccine
In order to evaluate the adjuvant capacity of IBLP1505, we
selected an oral pentavalent vaccine that contains five live
reassortant rotaviruses. Then, mice were immunized on days
0, 14, and 28 by the oral route with the rotavirus vaccine and
IBLP1505 as described in detail in the materials and methods
section. Mice orally immunized with the vaccine alone or added
with viable L. rhamnosus CRL1505 were used for comparisons.
The levels of rotavirus-specific intestinal IgA and serum IgG
were determined seven days after the last immunization. In a
first set of experiments, mice were vaccinated with 30 µl of
vaccine and 108 bacterial cells or particles (high vaccine/low
adjuvant immunization protocol). As shown in Figure 2A, both
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FIGURE 1 | Transmission electron microscopy analysis. (A) Lactobacillus
rhamnosus CRL1505 untreated cells and (B) bacterium-like particles obtained
from L. rhamnosus CRL1505 (IBLP1505) were fixed with Karnovsky fixative,
postfixed with 1% osmium tetroxide in sodium phosphate buffer and
embedded in Spurr resin. Ultrathin sections cuts were examined with a Zeiss
libra 120 Transmission Electron Microscope.
intestinal and serum specific antibodies were detected in control
mice indicating that the vaccine induced mucosal and systemic
humoral immune responses in ourmodel. The levels of rotavirus-
specific intestinal IgA and serum IgG in mice immunized
with the rotavirus vaccine and IBLP1505 were significantly
higher when compared to controls (Figure 2A). In addition,
intestinal IgA in mice immunized with the rotavirus vaccine
and viable L. rhamnosus CRL1505 were significantly higher
than controls. However, in this group of mice, the levels of
serum specific IgG antibodies were not different from controls
(Figure 2A).
In a second set of experiments, we evaluated whether the
dose of rotavirus vaccine could be reduced by using a higher
dose of IBLP1505 (low vaccine/high adjuvant immunization
protocol). Then, mice were vaccinated with 7.5 µl of vaccine
and 109 bacterial cells or particles. As shown in Figure 2B,
the levels of intestinal rotavirus-specific IgA did not change in
comparison with the previous vaccination protocol. However,
a significant reduction of serum specific IgG antibodies was
detected. The levels of intestinal IgA and serum IgG antibodies in
mice immunized with the rotavirus vaccine and IBLP1505 were
significantly higher than controls (Figure 2B). We also observed
that intestinal IgA levels were higher and that serum IgG levels
were lower than the values obtained in the first immunization
protocol (Figure 2A). Interestingly, the group of mice receiving
the low vaccine dose together with viable L. rhamnosus CRL1505
had rotavirus-specific intestinal IgA and serum IgG antibodies
that were not different from controls (Figure 2B).
IBLP From L. rhamnosus CRL1505
Enhance the Mucosal Cellular Immune
Response Against Rotavirus Vaccine
We next evaluated whether the two immunization protocols
were able to modify the mucosal and systemic cellular immune
elicited by rotavirus vaccine. First, we evaluated the proportion
of CD3+CD4+ and CD3+CD8+ T cells as well as CD24+B220+
B cells in Peyer’s patches of vaccinated mice. In the high
vaccine/low IBLP1505 immunization protocol (Figure 3A),
the vaccination of control mice did not induce significant
changes in CD3+CD4+, CD3+CD8+, or CD24+B220+ cells
percentages when compared with non-immunized mice (data
not shown). In addition, no differences were observed in
CD3+CD4+ and CD3+CD8+ T cells when mice immunized
with rotavirus vaccine and IBLP1505 or viable L. rhamnosus
CRL1505 were compared to controls. However, the vaccination
protocols that included IBLP1505 or viable L. rhamnosus
CRL1505 as adjuvants significantly increased the proportion
of CD24+B220+ B cells in Peyer’s patches when compared
to controls (Figure 3A). In the low vaccine/high adjuvant
immunization protocol (Figure 3B), the vaccination of mice
with the rotavirus vaccine and IBLP1505 significantly increased
CD3+CD4+ T cells as well as CD24+B220+ B cells in Peyer’s
patches. Mice, which received rotavirus vaccine and viable L.
rhamnosus CRL1505 only had significantly higher CD3+CD4+
T cells than controls (Figure 3B). No significant differences
between the groups were observed regarding CD3+CD8+ T
cell counts.
We then assessed the ability of immune cells obtained from
the Peyer’s patches of vaccinated mice to induce cytokines in
response to the ex vivo stimulation with the rotavirus vaccine.
For this purpose, isolated immune cells were cultured and
after challenging them with rotavirus the levels of TNF-α,
IFN-γ and IL-4 were evaluated in the supernatants (Figure 4).
As expected, the vaccination of control mice with the two
protocols used in this work significantly increased the production
of TNF-α, IFN-γ, and IL-4 by Peyer’s patches immune cells
in response to vaccine stimulation when compared with
non-immunized mice (data not shown). In addition, both
the high vaccine/low IBLP1505 and the low vaccine/high
IBLP1505 immunization protocols significantly enhanced the
production of TNF-α, IFN-γ, and IL-4 when compared to the
control group (Figure 4). Similarly, the vaccination protocols
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FIGURE 2 | Effect of immunobiotic bacterium-like particles obtained from Lactobacillus rhamnosus CRL1505 (IBLP1505) on the humoral immune response induced
by the immunization of mice with an oral rotavirus vaccine. Mice (4-week-old) were immunized on days 0, 14, and 28 by the oral route with the rotavirus vaccine and
IBLP1505 as adjuvant. Mice orally vaccinated with rotavirus vaccine only (controls) and mice receiving the vaccine with viable L. rhamnosus CRL1505 as adjuvant
were used for comparisons. Two immunization protocols were used: (A) each mouse was vaccinated with 30 µl of vaccine and 108 bacterial cells or particles; (B)
each mouse was vaccinated with 7.5 µl of vaccine and 109 bacterial cells or particles. Seven days after the last immunization, serum, and intestinal fluid samples were
obtained for the determination of IgA and IgG specific antibodies. Each experimental group consisted of 3 mice per group and experiments were performed in
triplicate (n = 9). Results were expressed as mean ± standard deviation. Differences were considered significant at P < 0.05 when compared with animals immunized
with rotavirus vaccine only (*).
using viable L. rhamnosus CRL1505 as adjuvant increased
the levels of these cytokines when compared to control mice
(Figure 4).
IBLP From L. rhamnosus CRL1505
Enhance the Systemic Cellular Immune
Response Against Rotavirus Vaccine
The proportions of CD3+CD4+ and CD3+CD8+ T cells as
well as CD24+B220+ B cells in spleen of vaccinated mice
were also evaluated. No significant differences were observed
between the groups when these immune cell populations were
evaluated for both immunization protocols (data not shown). In
addition, the levels of TNF-α, IFN-γ, and IL-4 were quantified
in the supernatants of cultured isolated immune cells from
spleens after the challenge with the rotavirus vaccine (Figure 5).
In the high vaccine/low IBLP1505 or viable L. rhamnosus
CRL1505 immunization protocols (Figure 5A), the vaccination
with rotavirus vaccine and adjuvants significantly increased
the production of TNF-α, IFN-γ, and IL-4 by splenocytes
when compared to controls. Interestingly, the levels of TNF-α
and IFN-γ were significantly higher in mice immunized with
viable L. rhamnosus CRL1505 than in those receiving IBLP1505
(Figure 5A). On the other hand, in the low vaccine/high
IBLP1505 or viable L. rhamnosus CRL1505 immunization
protocols (Figure 5B), the vaccination of mice significantly
enhanced the production of the three cytokines by splenocytes
when compared to controls.
The Adjuvant Capacities of BLP From
Lactobacilli Are Strain-Dependent
Finally, we aimed to evaluate whether the adjuvant capacity
of IBLP1505 was a strain characteristic or if it was shared
by BLP derived from other immunomodulatory strains. Then,
we obtained BLP from the immunomodulatory strains L.
rhamnosus IBL027 and L. plantarum CRL1506 and from the
non-immunomodulatory strain L. plantarum CRL1905. The
particles were designated as IBLP027, IBLP1506, and BLP1905
and used to immunize mice with the low vaccine/high adjuvant
immunization protocol. As shown in Figure 6, IBLP027 was as
effective as IBLP1505 to improve the production of rotavirus-
specific intestinal IgA and serum IgG antibodies. In addition,
intestinal IgA in mice immunized with the rotavirus vaccine
and IBLP1506 were significantly higher than controls. However,
these antibodies were lower when compared to those in mice
receiving IBLP027 or IBLP1505 (Figure 6). The immunization
with BLP1905 was not able to significantly change the levels of
rotavirus-specific intestinal IgA and serum IgG antibodies when
compared to controls.
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FIGURE 3 | Effect of immunobiotic bacterium-like particles obtained from Lactobacillus rhamnosus CRL1505 (IBLP1505) on the cellular immune response induced by
the immunization of mice with an oral rotavirus vaccine. Mice (4-week-old) were immunized on days 0, 14, and 28 by the oral route with the rotavirus vaccine and
IBLP1505 as adjuvant. Mice orally vaccinated with rotavirus vaccine only (controls) and mice receiving the vaccine with viable L. rhamnosus CRL1505 as adjuvant
were used for comparisons. Two immunization protocols were used: (A) each mouse was vaccinated with 30 µl of vaccine and 108 bacterial cells or particles; (B)
each mouse was vaccinated with 7.5 µl of vaccine and 109 bacterial cells or particles. Seven days after the last immunization, Peyer’s patches samples were obtained
for the study of CD3+CD4+, CD3+CD8+ T and CD24+B220+ B cells within the CD45+ population by flow cytometry. Each experimental group consisted of 3 mice
per group and experiments were performed in triplicate (n = 9). Results were expressed as mean ± standard deviation. Differences were considered significant at P <
0.05 when compared with animals immunized with rotavirus vaccine only (*).
In addition, we assessed the ability of immune cells obtained
from the Peyer’s patches and spleens of mice vaccinated with
IBLP027, IBLP1506, or BLP1905 to induce TNF-α, IFN-γ and
IL-4 in response to the ex vivo stimulation with rotavirus
(Figure 6). IBLP027 was as effective as IBLP1505 to improve
the production of TNF-α and IFN-γ by intestinal and spleen
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FIGURE 4 | Effect of immunobiotic bacterium-like particles obtained from Lactobacillus rhamnosus CRL1505 (IBLP1505) on the cellular immune response induced by
the immunization of mice with an oral rotavirus vaccine. Mice (4-week-old) were immunized on days 0, 14, and 28 by the oral route with the rotavirus vaccine and
IBLP1505 as adjuvant. Mice orally vaccinated with rotavirus vaccine only (controls) and mice receiving the vaccine with viable L. rhamnosus CRL1505 as adjuvant
were used for comparisons. Two immunization protocols were used: (A) each mouse was vaccinated with 30 µl of vaccine and 108 bacterial cells or particles; (B)
each mouse was vaccinated with 7.5 µl of vaccine and 109 bacterial cells or particles. Seven days after the last immunization, immune cells from Peyer’s patches
were isolated and in vitro stimulated with rotavirus vaccine. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ and interleukin (IL)-4 were measured in culture
supernatants. Each experimental group consisted of 3 mice per group and experiments were performed in triplicate (n = 9). Results were expressed as mean ±
standard deviation. Differences were considered significant at P < 0.05 when compared with animals immunized with rotavirus vaccine only (*).
immune cells in response to rotavirus challenge. Vaccination
with the rotavirus vaccine and IBLP1506 increased the levels of
IFN-γ produced by Peyer’s patches cells. However, this cytokine
was significantly lower when compared to the observed in mice
receiving IBLP027 or IBLP1505 (Figure 6). The immunization
with BLP1905 was not able to significantly change the levels
of TNF-α and IFN-γ produced by intestinal or spleen cells
when compared to controls. Similar to IBLP1505 (Figures 4, 5),
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FIGURE 5 | Effect of immunobiotic bacterium-like particles obtained from Lactobacillus rhamnosus CRL1505 (IBLP1505) on the cellular immune response induced by
the immunization of mice with an oral rotavirus vaccine. Mice (4-week-old) were immunized on days 0, 14, and 28 by the oral route with the rotavirus vaccine and
IBLP1505 as adjuvant. Mice orally vaccinated with rotavirus vaccine only (controls) and mice receiving the vaccine with viable L. rhamnosus CRL1505 as adjuvant
were used for comparisons. Two immunization protocols were used: (A) each mouse was vaccinated with 30 µl of vaccine and 108 bacterial cells or particles; (B)
each mouse was vaccinated with 7.5 µl of vaccine and 109 bacterial cells or particles. Seven days after the last immunization, immune cells from spleens were
isolated and in vitro stimulated with rotavirus vaccine. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ and interleukin (IL)-4 were measured in culture supernatants.
Each experimental group consisted of 3 mice per group and experiments were performed in triplicate (n = 9). Results were expressed as mean ± standard deviation.
Differences were considered significant at P < 0.05 when compared with animals immunized with rotavirus vaccine only (*) or between the indicated groups (**).
IBLP027, IBLP1506, and BLP1905 improved the levels of IL-4
in immune cells obtained from the Payer’s patches and spleens.
There was no statistical differences among the groups (data
not shown).
DISCUSSION
There is an urgent need to develop effective vaccines to
reduce the global burden of infectious disease in both humans
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FIGURE 6 | Effect of bacterium-like particles obtained from different lactobacilli strains on the immune response triggered by the immunization of mice with an oral
rotavirus vaccine. Mice (4-week-old) were immunized on days 0, 14, and 28 by the oral route with the rotavirus vaccine and bacterium-like particles from obtained
from the immunomodulatory strains L. rhamnosus CRL1505 (IBLP1505), L. rhamnosus IBL027 (IBLP027), and L. plantarum CRL1506 (IBLP1506) and from the
non-immunomodulatory strain L. plantarum CRL1905 (IBLP1905) as adjuvants. Mice orally vaccinated with rotavirus vaccine only (controls) were used for
comparisons. Each mouse was vaccinated with 7.5 µl of vaccine and 109 bacterial particles. Seven days after the last immunization, serum, and intestinal fluid
samples were obtained for the determination of IgA and IgG specific antibodies. In addition, immune cells from Peyer’s patches and spleen were isolated, cultured and
stimulated with rotaviral vaccine. TNF-α, and IFN-γ concentrations were determined in the supernatants by ELISA. Each experimental group consisted of 3 mice per
group and experiments were performed in triplicate (n = 9). Results were expressed as mean ± standard deviation. Differences were considered significant at
P < 0.05 when compared with animals immunized with rotavirus vaccine only (*) or between the indicated groups (**).
and animals. The use of mucosal vaccines triggers local and
systemic responses limiting the pathogens at the site of entry,
reducing their replication in epithelial cells, the alteration
of the epithelial barrier, and the action of toxins on the
mucosa. In addition, mucosal vaccination helps preventing
the spread of the pathogen to internal tissues and to the
environment (17, 18). Despite the several advantages of
mucosal vaccination, it faces many difficulties including poor
immunogenicity at low concentrations, chemical and enzymatic
degradation, potential toxicity, and the risk of generating
tolerance rather than protective immunity (17, 19). In this
work, we demonstrated that IBLP derived from highly efficient
immunomodulatory lactobacilli are an interesting alternative as
mucosal adjuvants.
It is well-documented that within the gastrointestinal tract,
immunomodulatory LAB are capable to interact with the
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host’s epithelial and immune cells, and thereby beneficially
influence epithelial barrier and immune functions (20). It
has been proposed that the final outcome of a host cell
response against beneficial immunomodulatory microorganisms
depends on the combination of distinct microbial-associated
molecular patterns (MAMPs) that can interact with various
pattern recognition receptors (PRRs) and associated co-receptors
to trigger different signaling pathways (20, 21). The unique
combination of cellular and molecular interactions that are
established between a certain microorganism with the host cells
explains why the immunomodulatory properties of LAB are
a strain dependent characteristic. The results of the present
work strongly suggest that the same principle could be applied
to IBLP derived from different LAB strains. In our hands,
IBLP derived from immunomodulatory L. rhamnosus CRL1505,
L. rhamnosus IBL027 and L. plantarum CRL1506 showed
adjuvant capacities when used together with the rotavirus vaccine
while the particles derived from the non-immunomodulatory L.
plantarum CRL1905 strain were not able to induce modifications
in the immune response triggered by the oral vaccination.
Moreover, our experiments demonstrated that the particles
derived from the immunomodulatory Lactobacillus strains had
different adjuvant capacities in terms of their ability to improve
the cellular and humoral immune responses triggered by
rotavirus vaccination.
Our previous comparative in vitro studies evaluating the
ability of L. rhamnosus CRL1505 and L. plantarum CRL1506
to modulate immune responses in intestinal epithelial cells and
antigen presenting cells (APCs) found significant differences
between the two lactobacilli strains (22, 23). It was demonstrated
that intestinal epithelial cells were modulated by immunobiotic
CRL1505 and CRL1506 in a strain-dependent fashion to
enhance antiviral responses (23). Interestingly, L. rhamnosus
CRL1505 was more efficient that L. plantarum CRL1506 to
increase the expression of IFN-β and IL-6 in intestinal epithelial
cells, both cytokines known to influence immune responses
generated by immune cells located under the epithelium. In
addition, both lactobacilli strains were reported to functionally
modulate APCs from porcine Peyer’s patches. However, L.
rhamnosus CRL1505 was more efficient than L. plantarum
CRL1506 to improve the expression of IL-1β, IL-6, and IFN-
γ in porcine CD172a+CD11R1high and CD172a−CD11R1low
dendritic cells (22). The improved Th1 response induced
by L. rhamnosus CRL1505 in porcine APCs was triggered
by TLR2 signaling and included augmented expression of
MHC-II and co-stimulatory molecules. Then, our previous
results would indicate that IBLP1505 is more efficient than
IBLP1506 to modulate the response of intestinal epithelial
cells and APCs to the challenge with attenuated rotavirus.
Moreover, it is tempting to speculate that IBLP1505 and
IBLP027 are able to interact more efficiently with intestinal
APCs than IBLP1506, inducing an increase in their activation
and antigenic presentation capacity, and generating effector
immune responses. In fact, both humoral and cellular intestinal
specific immune responses were significantly improved in mice
immunized with rotavirus vaccine and IBLP1505 or IBLP027
than in animals treated with the vaccine and IBLP1506,
indicating the different capacity of the particles to serve as
effective mucosal adjuvants.
Recombinant LAB expressing rotavirus antigens have
been evaluated as vaccine candidates (24–27). L. casei ATCC
393 (24) and L. lactis NZ9000 (25) expressing the major
protective antigen VP4 from rotavirus efficiently induced
the production of serum IgG and mucosal IgA anti-VP4
antibodies, which also demonstrated neutralizing effects on
rotavirus infection. Rodríguez-Díaz et al. (26), evaluated
the effect of the oral immunization of mice with L. lactis
expressing the rotavirus VP8 protein intracellularly and
extracellularly. Low mucosal IgA synthesis was found only
when the secreting L. lactis strain was used. On the other
hand, Esteban et al. (27), evaluated the immunogenicity
of the rotavirus VP6 protein expressed on the surface of
L. lactis. Authors described the ability of the recombinant
L. lactis VP6 to significantly increase the levels of specific
serum IgG antibodies although it should be mentioned
that the researchers used the subcutaneous route for the
immunization of mice. Despite the positive results obtained
with the aforementioned recombinant bacteria, there is still
general concern about the massive use of genetically modified
microorganisms because of the possibility of the introduction
of exogenous DNA in the intestinal microbiota, especially
plasmids that confer antibiotic resistance. The IBLPs evaluated
in this work can help to alleviate these concerns associated to
recombinant bacteria because they are non-genetically modified
and non-living.
By using a directed chromosomal integration approach,
Yin et al. (28) were able to develop a stable L. casei strain
expressing the porcine rotavirus VP4 antigen. The oral
immunization of mice with recombinant L. casei VP4
induced both specific intestinal and systemic humoral
immune responses. Although this improved chromosome
recombination and gene expression system could represent
an efficient method for safe vaccines production, it would
be necessary to design a recombinant bacterium for each
vaccine antigen (from the same virus or from different viruses),
which would significantly increase the cost of these types of
vaccines. On the other hand, IBLPs are able to incorporate
efficiently one or more different antigens on their surfaces,
which gives them an additional advantage over recombinant
bacteria, even with those that could be considered safe for
human use.
To the best of our knowledge, few reports have evaluated
the ability of non-living LAB as mucosal adjuvants and/or
delivery antigens for rotavirus vaccine development. Temprana
et al. (29), offered an option to the use of genetically modified
organisms in immunizations by obtaining cell wall-derived
fragments by mechanical rupture of a recombinant L. lactis
NZ9000 expressing a cell wall-anchored version of the rotavirus
VP6 protein. Authors evaluated the ability of those cell wall-
derived fragments containing the VP6 protein to induce specific
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immunity in mice by using intragrastric immunizations. The
report indicated that it was not possible to detect VP6-specific
serum IgG or IgA in the mice immunized intragastrically, even
when additional mucosal adjuvants were used. In addition, the
humoral immune response induced by the experimental vaccine
was evaluated while its impact on the specific cellular immune
response was not studied. In this work, we offer a different
alternative, which can be administered orally and efficiently
potentiate the local and systemic immune responses against
rotavirus. Furthermore, we demonstrate that our strategy not
only stimulate the humoral immunity but in addition, a specific
Th1 mucosal response can be also generated against the antigens
administered with IBLP. Our results suggest that the adjuvant
potential of IBLPs could also be exploited for subunit vaccines,
as it was the case of the hepatitis E virus (HEV) capsid protein
(ORF2) orally administered with IBLP1505 or IBLP027, which
induced both antigen-specific humoral and cellular immune
responses in mice (30). Then, the evaluation of the ability of
rotavirus antigens co-administered with IBLP or fused to a
LysM domain and expressed on the surface of IBLP to generate
specific protective immune responses is an interesting topic of
on-going research.
Some studies have demonstrated that the administration
of viable immunobiotic lactobacilli with attenuated rotavirus
vaccines significantly augment the ability of the vaccine to
stimulate the specific humoral immune response. In this regard,
by using a neonatal gnotobiotic pig model, Wen et al. (31)
demonstrated that orally administered L. rhamnosusGG increase
the levels of virus-specific intestinal IgA after vaccination
with attenuated human rotavirus. Similarly, L. acidophilus
NCFM improved rotavirus-specific antibody production as
well as memory B-cell responses to attenuated rotavirus
vaccine (32). In line with those studies, we showed here that
orally administered viable L. rhamnosus CRL1505 improved
the humoral immune response of rotavirus-vaccinated mice.
Interestingly, mice immunized with rotavirus vaccine and viable
L. rhamnosus CRL1505 showed lower intestinal IgA and serum
IgG specific antibodies than mice vaccinated with IBLP1505
as mucosal adjuvant. This phenomenon could be related to
the great ability of viable L. rhamnosus CRL1505 to stimulate
the innate antiviral intestinal immune responses (11–13, 22).
Transcriptomic studies revealed the capacity of L. rhamnosus
CRL1505 to differentially modulate the innate antiviral immune
response in porcine intestinal epithelial cells. Higher expression
levels of type I IFNs as well as in several antiviral factors
including ifit1, nlpr3, mda5, msx1, rig1 ifit2, and mx2 were
found in CRL1505-treated cells when compared to control cells
(23). In addition, it was demonstrated in vitro that viable
L. rhamnosus CRL1505 is able to efficiently stimulate the
expression of IFN-γ in porcine intestinal CD172a+CD11R1−
macrophages (22). Then, we hypothesize that the administration
of viable L. rhamnosus CRL1505 to mice would improve those
antiviral mechanisms in the intestinal mucosa, allowing a
rapid an efficient elimination of attenuated rotavirus included
in the vaccine formulation. The effective elimination of the
attenuated pathogens by the innate immune mechanisms would
be responsible for the lower interaction of rotavirus with
DCs and therefore for the lower stimulation of the adaptive
immune response. These results indicate that IBLP1505 has
an advantage with respect to viable bacteria to stimulate the
intestinal and systemic specific adaptive immune responses
to attenuated virus. However, it is important to investigate
and compare the ability of viable L. rhamnosus CRL1505
and IBLP1505 to stimulate the adaptive immune responses
when subunit vaccines are used instead of vaccines based on
attenuated pathogens.
There is a growing need for the development of new and
improved mucosal vaccines to diminish the morbidity and
mortality associated to infectious diseases, particularly against
those targeting the respiratory and gastrointestinal tracts (17,
18). The search and characterization of mucosal adjuvants
to enhance the immunity against antigens is of fundamental
importance to advance in this path. In this regard, BLPs
obtained from immunomodulatory beneficial microorganisms
are an interesting alternative. Our findings indicate that an
appropriate selection of BLPs is necessary in order to find those
with the most efficient adjuvant properties. We propose the
term Immunobiotic-like particles (IBLPs) for the BLPs derived
from highly immunomodulatory strains such as L. rhamnosus
CRL1505 and L. rhamnosus IBL027 that are a promising
alternative for the development of mucosal vaccines.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The animal study was reviewed and approved by the CERELA
Institutional Animal Care andUse Committee under the protocol
BIOT-CRL-18. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Guidelines for Animal
Experimentation of CERELA.
AUTHOR’S NOTE
FR and LA hold CONICET scholarships. SS, SA, MV-P, and JV
are members of CONICET.
AUTHOR CONTRIBUTIONS
JV and MV-P designed the study and wrote the manuscript. FR,
LA, and SS did the experiments. MV-P, JV, HK, and HT provided
financial support. JV, MV-P, HK, and SA contributed to data
analysis and results interpretation.
FUNDING
This study was supported by grants of the Agencia Nacional de
Ciencia y Técnica (PICT-2016-0853 and 1314 PICT-2016-0410),
CONICET (PIP057), and Fundación Allende to JV and MV-P.
Frontiers in Immunology | www.frontiersin.org 11 January 2020 | Volume 11 | Article 15
Raya Tonetti et al. Immunobiotic-Like Particles as Mucosal Adjuvants
This study was also supported by a Grant-in-Aid for Scientific
Research (A) (19H00965), (B) (16H05019) and Open Partnership
Joint Projects of JSPS Bilateral Joint Research Projects from the
Japan Society for the Promotion of Science (JSPS), and by grants
from the project of NARO Bio-oriented Technology Research
Advancement Institution (Research Program on development
of innovation technology, No. 01002A) to HK, and also the
grants for Scientific Research on Innovative Areas from the
Ministry of Education, Culture, Science, Sports, and Technology
(MEXT) of Japan (Grant numbers: 16H06429, 16K21723,
and 16H06435) to HT. This work was also supported by
JSPS Core-to-Core Program, A. Advanced Research Networks
entitled Establishment of international agricultural immunology
research-core for a quantum improvement in food safety.
REFERENCES
1. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Alcocer-Gonzalez JM,
Tamez-Guerra RS, de Oca-Luna RM, et al. An inducible surface presentation
system improves cellular immunity against human papillomavirus type 16 E7
antigen in mice after nasal administration with recombinant lactococci. J Med
Microbiol. (2004) 53:427–33. doi: 10.1099/jmm.0.05472-0
2. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Gruss A, Rodriguez-
Padilla C, Saucedo-Cardenas O, et al. Fusion to a carrier protein and
a synthetic propeptide enhances E7 HPV-16 production and secretion in
Lactococcus lactis. Biotechnol Prog. (2003) 19:1101–4. doi: 10.1021/bp0340077
3. Villena J, Medina M, Raya R, Alvarez S. Oral immunization with recombinant
Lactococcus lactis confers protection against respiratory pneumococcal
infection. Can J Microbiol. (2008) 54:845–53. doi: 10.1139/W08-077
4. Szatraj K, Szczepankowska AK, Chmielewska-Jeznach M. Lactic acid bacteria
- promising vaccine vectors: possibilities, limitations, doubts. J Appl Microbiol.
(2017) 123:325–39. doi: 10.1111/jam.13446
5. Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, van
Deemter M, et al. Lactococcus lactis GEM particles displaying pneumococcal
antigens induce local and systemic immune responses following intranasal
immunization.Vaccine. (2006) 24:5434–41. doi: 10.1016/j.vaccine.2006.03.054
6. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen
A, et al. Novel surface display system for proteins on non-genetically
modified gram-positive bacteria. Appl Environ Microbiol. (2006) 72:880–
9. doi: 10.1128/AEM.72.1.880-889.2006
7. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J,
Leenhouts K. Immunogenicity of a malaria parasite antigen
displayed by Lactococcus lactis in oral immunisations. Vaccine. (2006)
24:3900–8. doi: 10.1016/j.vaccine.2006.02.040
8. van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S,
Bosma T, et al. Mucosal vaccine delivery of antigens tightly bound to an
adjuvant particle made from food-grade bacteria. Methods. (2006) 38:144–
9. doi: 10.1016/j.ymeth.2005.09.015
9. Nganou-Makamdop K, van Roosmalen ML, Audouy SA, van Gemert
GJ, Leenhouts K, Hermsen CC, et al. Bacterium-like particles as multi-
epitope delivery platform for Plasmodium berghei circumsporozoite protein
induce complete protection against malaria in mice. Malaria J. (2012)
11:50. doi: 10.1186/1475-2875-11-50
10. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A,
Hinrichs WL, et al. Intranasal delivery of influenza subunit vaccine
formulated with GEM particles as an adjuvant. AAPS J. (2010) 12:109–
16. doi: 10.1208/s12248-009-9168-2
11. Salva S, Villena J, Alvarez S. Immunomodulatory activity of
Lactobacillus rhamnosus strains isolated from goat milk: impact on
intestinal and respiratory infections. Int J Food Microbiol. (2010)
141:82–9. doi: 10.1016/j.ijfoodmicro.2010.03.013
12. Villena J, Chiba E, Tomosada Y, Salva S, Marranzino G, Kitazawa H,
et al. Orally administered Lactobacillus rhamnosus modulates the respiratory
immune response triggered by the viral pathogen-associated molecular
pattern poly(I:C). BMC Immunol. (2012) 13:53. doi: 10.1186/1471-217
2-13-53
13. Tada A, Zelaya H, Clua P, Salva S, Alvarez S, Kitazawa H, et al. Immunobiotic
Lactobacillus strains reduce small intestinal injury induced by intraepithelial
lymphocytes after Toll-like receptor 3 activation. Inflamm Res. (2016) 65:771–
83. doi: 10.1007/s00011-016-0957-7
14. Medina M, Villena J, Salva S, Vintini E, Langella P, Alvarez S. Nasal
administration of Lactococcus lactis improves local and systemic immune
responses against Streptococcus pneumoniae. Microbiol Immunol. (2008)
52:399–409. doi: 10.1111/j.1348-0421.2008.00050.x
15. Barbieri N, Villena J, Herrera M, Salva S, Alvarez S. Nasally administered
Lactobacillus rhamnosus accelerate the recovery of humoral immunity
in B lymphocyte-deficient malnourished mice. J Nutr. (2013) 143:227–
35. doi: 10.3945/jn.112.165811
16. Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H,
et al. Nasally administered Lactobacillus rhamnosus strains differentially
modulate respiratory antiviral immune responses and induce protection
against respiratory syncytial virus infection. BMC Immunol. (2013)
14:40. doi: 10.1186/1471-2172-14-40
17. Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M. Mucosal
vaccines: a paradigm shift in the development of mucosal adjuvants and
delivery vehicles. Acta Pathol Microbiol Immunol Scand. (2015) 123:275–
88. doi: 10.1111/apm.12351
18. Miquel-Clopes A, Bentley EG, Stewart JP, Carding SR. Mucosal vaccines and
technology. Clin Exp Immunol. (2019) 196:205–14. doi: 10.1111/cei.13285
19. Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine
design and delivery. Annu Rev Biomed Eng. (2012) 14:17–
46. doi: 10.1146/annurev-bioeng-071811-150054
20. Villena J, Vizoso-Pinto MG, Kitazawa H. Intestinal innate antiviral
immunity and immunobiotics: beneficial effects against rotavirus
infection. Front Immunol. (2016) 7:563. doi: 10.3389/fimmu.2016.
00563
21. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of
probiotic bacterial surface molecules: comparison with commensals and
pathogens. Nat Rev Microbiol. (2010) 8:171–84. doi: 10.1038/nrmicro
2297
22. Villena J, Chiba E, Vizoso-Pinto MG, Tomosada Y, Takahashi T,
Ishizuka T, et al. Immunobiotic Lactobacillus rhamnosus strains
differentially modulate antiviral immune response in porcine intestinal
epithelial and antigen presenting cells. BMC Microbiol. (2014)
14:126. doi: 10.1186/1471-2180-14-126
23. Albarracin L, Kobayashi H, Iida H, Sato N, Nochi T, Aso H, et al.
Transcriptomic analysis of the innate antiviral immune response
in porcine intestinal epithelial cells: influence of immunobiotic
lactobacilli. Front Immunol. (2017) 8:57. doi: 10.3389/fimmu.2017.
00057
24. Qiao X, Li G, Wang X, Li X, Liu M, Li Y. Recombinant porcine
rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced
mucosal and systemic antibody responses in mice. BMC Microbiol. (2009)
9:249. doi: 10.1186/1471-2180-9-249
25. Li YJ, Ma GP, Li GW, Qiao XY, Ge JW, Tang LJ, et al. Oral
vaccination with the porcine rotavirus VP4 outer capsid protein
expressed by Lactococcus lactis induces specific antibody production.
J Biomed Biotechnol. (2010) 2010:708460. doi: 10.1155/2010/
708460
26. Rodríguez-Díaz J, Montava R, Viana R, Buesa J, Pérez-Martínez
G, Monedero V. Oral immunization of mice with Lactococcus
lactis expressing the rotavirus VP8 protein. Biotechnol Lett. (2011)
33:1169–75. doi: 10.1007/s10529-011-0551-6
27. Esteban LE, Temprana CF, Argüelles MH, Glikmann G, Castello
AA. Antigenicity and immunogenicity of rotavirus VP6 protein
Frontiers in Immunology | www.frontiersin.org 12 January 2020 | Volume 11 | Article 15
Raya Tonetti et al. Immunobiotic-Like Particles as Mucosal Adjuvants
expressed on the surface of Lactococcus lactis. Biomed Res Int. (2013)
2013:298598. doi: 10.1155/2013/298598
28. Yin JY, Guo CQ, Wang Z, Yu ML, Gao S, Bukhari SM, et al. Directed
chromosomal integration and expression of porcine rotavirus outer capsid
protein VP4 in Lactobacillus casei ATCC393. Appl Microbiol Biotechnol.
(2016) 100:9593–604. doi: 10.1007/s00253-016-7779-y
29. Temprana CF, Argüelles MH, Gutierrez NM, Barril PA, Esteban
LE, Silvestre D, et al. Rotavirus VP6 protein mucosally delivered
by cell wall-derived particles from Lactococcus lactis induces
protection against infection in a murine model. PLoS ONE. (2018)
13:e0203700. doi: 10.1371/journal.pone.0203700
30. Arce LP, Raya Tonetti MF, Raimondo MP, Müller MF, Salva S, Alvarez S,
et al. Oral vaccination with hepatitis E Virus capsid protein and immunobiotic
bacterium-like particles induce intestinal and systemic immunity in
mice. Probiot Antimicrob Proteins. (2019). doi: 10.1007/s12602-019-09
598-7
31. Wen K, Liu F, Li G, Bai M, Kocher J, Yang X, et al. Lactobacillus
rhamnosus GG dosage affects the adjuvanticity and protection against
rotavirus diarrhea in gnotobiotic pigs. J Pediatr Gastroenterol Nutr. (2015)
60:834–43. doi: 10.1097/MPG.0000000000000694
32. Liu F, Wen K, Li G, Yang X, Kocher J, Bui T, et al. Dual
functions of Lactobacillus acidophilus NCFM as protection
against rotavirus diarrhea. J Pediatr Gastroenterol Nutr. (2014)
58:169–76. doi: 10.1097/MPG.0000000000000197
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Raya Tonetti, Arce, Salva, Alvarez, Takahashi, Kitazawa, Vizoso-
Pinto and Villena. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 13 January 2020 | Volume 11 | Article 15
